Physician profile
Gertha Boucicault
NPI 1619285814
$753.92
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $213 · 2023: $70.04 · 2024: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $541.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.43 | 2022-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $143.34 | 2024 | Airsupra |
| Lilly USA, LLC | $140.23 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $89.18 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.19 | 2023-2024 | Xifaxan |
| Novo Nordisk INC | $30.02 | 2023-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $29.56 | 2024 | |
| Amgen INC. | $23.02 | 2024 | Repatha, Otezla |
| Eisai INC. | $20.98 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.28 | 2022 | |
| Exact Sciences Corporation | $17.69 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gertha Boucicault listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.